Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
20 Apr 2021

AbbVie challenges J&J with Skyrizi PsA submission

AbbVie has announced its submission to the US Food and Drug Administration (FDA) for its selective interleukin (IL)-23 inhibitor Skyrizi (risankizumab) for the indication of psoriatic arthritis (PsA). If approved,…